Comprehensive molecular analysis of pediatric thalamic tumors

Childhood thalamic tumors are rare types of brain cancer that make up about 5% of all brain tumors in children. These tumors usually originate from a type of brain cell called glial cells, and they can be classified as either low grade (less aggressive) or high grade (more aggressive) gliomas based on their appearance under the microscope.
Recent research has reclassified thalamic tumors along with other similar brain tumors under the umbrella of midline gliomas. This reclassification was driven by discoveries showing that mutations in certain genes related to histones (proteins that package DNA) play a crucial role in these cancers. Specifically, mutations in genes encoding histone 3 variants (such as H3.3, H3.2, and H3.1) are frequently found in these tumors. Thalamic tumors can affect one or both sides of the thalamus (a part of the brain) and can even spread to the brainstem. Bilateral thalamic gliomas, where both sides of the thalamus are involved, are particularly rare and generally have a poor prognosis because they are difficult to surgically remove completely. High grade thalamic gliomas with a specific histone mutation (H3.3K27M) are associated with worse overall survival rates. While significant progress has been made in understanding these tumors, more research is needed to fully understand their genetic abnormalities and to develop targeted therapies. Our study aims to conduct a comprehensive analysis of the genetic makeup of thalamic tumors using advanced techniques like whole genome sequencing, methylation analysis, and proteomics. By studying a large collection of tumor samples, including both primary tumors and those with metastases to the thalamus, we aim to identify new genetic mutations and pathways that could be driving these cancers.